The effect of comorbidity on survival and collected CD34+cell counts in autologous hematopoietic stem cell transplant patients

SARICI A., ERKURT M. A., KUKU İ., Bahcecioglu O. F., Bicim S., KAYA E., ...Daha Fazla

TRANSFUSION AND APHERESIS SCIENCE, cilt.61, sa.1, 2022 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 61 Sayı: 1
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1016/j.transci.2021.103296
  • Dergi Adı: TRANSFUSION AND APHERESIS SCIENCE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, EMBASE, MEDLINE
  • Anahtar Kelimeler: Autologous stem cell transplantation, Lymphoma, Multiple myeloma, Hematopoietic cell transplantation-specific co, morbidity index, Engraftment time, INDEX HCT-CI, REDUCED-INTENSITY, LYMPHOMA PATIENTS, MULTIPLE-MYELOMA, ELDERLY-PATIENTS, PREDICTS, OUTCOMES, BLOOD, MORTALITY
  • İnönü Üniversitesi Adresli: Evet

Özet

Objective: In this study, we aimed to report the effectiveness of hematopoietic cell transplantation-specific comorbidity index (HCT-CI) and GATMO scores in predicting overall survival (OS) who underwent autologous stem cell transplantation (ASCT). Material and methods: The data of 263 MM and 204 lymphoma patients who underwent ASCT in the last 11 years were retrospectively analyzed. Results: Neutrophil engraftment time, thrombocyte engraftment time and collected CD34+ cell counts were similar in MM patients with HCT-CI 2 (all p 2 tended to be higher than those with HCT-CI 2 was 51.5 months, the estimated median OS of patients with HCT-CI 2 was 9.5 months (p=0.012). When lymphoma patients were divided into four groups according to their GATMO scores, the OS of the four groups was found to be different from each other (p<0.001). Conclusion: HCT-CI and GATMO scores predict OS in lymphoma patients but not MM patients.